Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Inhibitors of the PI3K pathway are in clinical testing in patients with solid tumors, including uterine cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP316903.RAmDb_o9K4Tj5yo_XqPR2H9YL360MJm8qi2rYclSvHxaY130_assertion description "[Inhibitors of the PI3K pathway are in clinical testing in patients with solid tumors, including uterine cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP316903.RAmDb_o9K4Tj5yo_XqPR2H9YL360MJm8qi2rYclSvHxaY130_provenance.
• NP570625.RA74Sksptea_l9dZHsdJWethTuiNlNUiBDwvfv5Yi2cfw130_assertion description "[Inhibitors of the PI3K pathway are in clinical testing in patients with solid tumors, including uterine cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP570625.RA74Sksptea_l9dZHsdJWethTuiNlNUiBDwvfv5Yi2cfw130_provenance.
• NP566653.RA7aYBF-0vtuW2wEHWrV1XMC_KATIeRr0aWgve-qBFm_g130_assertion description "[Inhibitors of the PI3K pathway are in clinical testing in patients with solid tumors, including uterine cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP566653.RA7aYBF-0vtuW2wEHWrV1XMC_KATIeRr0aWgve-qBFm_g130_provenance.
• NP714586.RAxJ20XJDOCK1EaY_nmZNU0v4pT_t-gkV3IcM1WhGisdg130_assertion description "[Inhibitors of the PI3K pathway are in clinical testing in patients with solid tumors, including uterine cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP714586.RAxJ20XJDOCK1EaY_nmZNU0v4pT_t-gkV3IcM1WhGisdg130_provenance.
• NP622844.RAZ_jW9idRvkZlE3iceLlRhI5B5Tj4g5lMiCv8Thv-MJA130_assertion description "[Inhibitors of the PI3K pathway are in clinical testing in patients with solid tumors, including uterine cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP622844.RAZ_jW9idRvkZlE3iceLlRhI5B5Tj4g5lMiCv8Thv-MJA130_provenance.
• NP558757.RAJLZw3KuBTFfJSYxFhx03TufFF-y3pxDy6qUdUuSTxE8130_assertion description "[Inhibitors of the PI3K pathway are in clinical testing in patients with solid tumors, including uterine cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP558757.RAJLZw3KuBTFfJSYxFhx03TufFF-y3pxDy6qUdUuSTxE8130_provenance.
• NP528282.RANWGxszhFCH-DG6k54BlziKt-0HvjNgvXfde4tgl7Zas130_assertion description "[Inhibitors of the PI3K pathway are in clinical testing in patients with solid tumors, including uterine cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP528282.RANWGxszhFCH-DG6k54BlziKt-0HvjNgvXfde4tgl7Zas130_provenance.
• assertion description "[Inhibitors of the PI3K pathway are in clinical testing in patients with solid tumors, including uterine cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Inhibitors of the PI3K pathway are in clinical testing in patients with solid tumors, including uterine cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Inhibitors of the PI3K pathway are in clinical testing in patients with solid tumors, including uterine cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Inhibitors of the PI3K pathway are in clinical testing in patients with solid tumors, including uterine cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP621575.RAAr2CS2XyXvAoOG2Vfm0dQ1ligHGOQX0SxLMI82OszLk130_assertion description "[Inhibitors of the PI3K pathway are in clinical testing in patients with solid tumors, including uterine cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP621575.RAAr2CS2XyXvAoOG2Vfm0dQ1ligHGOQX0SxLMI82OszLk130_provenance.
• NP922347.RATn-Mu-dSPJ0_ft9BvY0j30I2VNbKQmyjVerJBD5_B7c130_assertion description "[Inhibitors of the PI3K pathway are in clinical testing in patients with solid tumors, including uterine cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP922347.RATn-Mu-dSPJ0_ft9BvY0j30I2VNbKQmyjVerJBD5_B7c130_provenance.
• NP625300.RAmzGCmIrF82bxahRhyGyl3UJQS9fPVIyc8t14MXDyOHE130_assertion description "[Inhibitors of the PI3K pathway are in clinical testing in patients with solid tumors, including uterine cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP625300.RAmzGCmIrF82bxahRhyGyl3UJQS9fPVIyc8t14MXDyOHE130_provenance.
• NP922343.RAiOZ5RxwFHlO2Rfw7SsDONGYDQOUSyKE26cWNCPF8m6I130_assertion description "[Inhibitors of the PI3K pathway are in clinical testing in patients with solid tumors, including uterine cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP922343.RAiOZ5RxwFHlO2Rfw7SsDONGYDQOUSyKE26cWNCPF8m6I130_provenance.
• NP624160.RA2s-RCrNnCIMRlAR7HopwY-ap1959iff7eytC36BoXvo130_assertion description "[Inhibitors of the PI3K pathway are in clinical testing in patients with solid tumors, including uterine cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP624160.RA2s-RCrNnCIMRlAR7HopwY-ap1959iff7eytC36BoXvo130_provenance.
• NP922342.RALOlfjIn3KZ-6Zvv_Wv0KppJjIIkmo8vVxRVhab9JsAQ130_assertion description "[Inhibitors of the PI3K pathway are in clinical testing in patients with solid tumors, including uterine cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP922342.RALOlfjIn3KZ-6Zvv_Wv0KppJjIIkmo8vVxRVhab9JsAQ130_provenance.
• NP922344.RAMRDK4d8Gq8gYAGMLKptdFSoDd-kAooiYN90_p0KWcII130_assertion description "[Inhibitors of the PI3K pathway are in clinical testing in patients with solid tumors, including uterine cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP922344.RAMRDK4d8Gq8gYAGMLKptdFSoDd-kAooiYN90_p0KWcII130_provenance.